This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
Workshop will be on ‘Ophthalmic DrugDelivery Development – Trials and Tribulations’. Ophthalmic DrugDelivery is compelling for many reasons, including the major issue of patient compliance and tolerability of therapies. Ophthalmic Drugs Conference. Hosted by Brian Levy, CEO, Ocunexus Therapeutics.
Sustainability for Injectable Delivery Devices. Primary Packaging Development. Connected DrugDelivery Devices. Delve into the considerations for material components for the development of primary packaging. Kevin Kusmierek, Scientist, Primary Packaging and Medical Devices, CSL Behring.
The Future of DrugDelivery and Combination Product Device Design. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.
A corporate compliance training program is a part of many onboarding programs to ensure employees are up to date with the latest rules and regulations they must adhere to while working for the company. Novartis trains and guides associates with a structured program consisting of ethics, risk and compliance.
They offer several advantages over traditional drugdelivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Prefilled syringes are syringes that come pre-filled with a specific dose of medication.
In order to help circumvent these disadvantages, several drugdelivery devices, which enable patients to self-administer drugs through subcutaneous route are now being developed. Currently, antibodies segment is likely to occupy the largest share in the overall market.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content